Skip to content

Cream Containing Sericin and Turmeric in Psoriasis Patients

Efficacy and Safety of Cream Containing Sericin and Turmeric in Psoriasis Patients

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06482398
Enrollment
30
Registered
2024-07-01
Start date
2024-07-01
Completion date
2025-07-31
Last updated
2024-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Brief summary

Psoriasis lesion is divided into two parts. Half of the lesion will apply cream containing sericin and turmeric and another will apply steroid cream (control). The samples will be apply two times a day for 8 weeks. Psoriasis area and severity index, physician global assessment, body surface area of lesion, dermatology life quality index, Itching score, adverse reaction are evaluated before, after using the samples for 4 and 8 weeks.

Interventions

DRUGSericin extract and turmeric extract cream

Apply the sample 2 times a day for 8 weeks

DRUGTriamcinolone acetonide 1% Cream

Apply the sample 2 times a day for 8 weeks

Sponsors

Chulalongkorn University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age over 18 years * Patients with body surface area of psoriasis lesion less than 10, have psoriasis area and severity index less than 10 , and no lesion at face, hands,feet, and genital area * No topical application on psoriasis lesion at least 2 weeks * Willing to attend the study

Exclusion criteria

* Uncontrolled diseases * Allergic to sericin turmeric and steroid * Other skin diseases * Pregnancy and lactation

Design outcomes

Primary

MeasureTime frameDescription
Psoriasis Area and Severity Index8 weeksPhysician will evaluate the psoriasis lesion using Psoriasis Area and Severity Index. The score is graded 0 to 72 (low score means less severity and high score means high severity).

Secondary

MeasureTime frameDescription
Physician Global Assessment8 weeksPhysician will evaluate the psoriasis lesion using Physician Global Assessment score (0 to 6, 0 means completely cleared, except for possible residual nonerythematous discoloration and 6 means condition worsened).
Body surface area of lesion8 weeksPhysician will evaluate body surface area of psoriasis lesion in percentage. (low percentage means the lesion area decrease and high percentage means the lesion area increase).
Dermatology Life Quality Index8 weeksPatients will assess dermatology life quality score (0 to 30, 0 means high life quality and 30 means low life quality).
Itching score8 weeksPatients will assess itching score using visual analogue scale (0 to 10, 0 means low severity and 10 means high severity).

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026